Bioconjugate Chemistry · 2006 · 37 citations · 29 references
MedicineNuclear MedicineOncologyCancer PharmacologyMolecular ImagingTherapeutic Nuclear MedicineLigand BindingPharmacokinetics Of Anticancer DrugsRadiopharmaceutical DesignRadiopharmaceutical TherapyRadiotracer DevelopmentTargeted RadiopharmaceuticalsBiodistribution EnhancementBiodistribution StudiesIn Vivo ImagingPeptide ConjugatesPeptide-drug ConjugatesRadionuclide BiodistributionRadiotracer SynthesisTumor Uptake Mechanisms
This report describes synthesis of three new cyclic RGDfK peptide conjugates, HYNIC-PKM-SU016 (PKM = E, K and PEG4) and in vivo evaluation of the impact of PKM linkers on biodistribution characteristics of their ternary ligand complexes [99mTc(HYNIC-PKM-SU016)1(tricine)(TPPTS)] in athymic nude mice bearing the MDA-MB-435 human breast cancer xenografts. Results from biodistribution studies show that PKM linkers have minimal impact on the integrin alphavbeta3 binding capability of radiotracers. Even though they have different charges under physiological conditions, all three linkers (E, K, and PEG4) are able to reduce the uptake of 99mTc-labeled E[c(RGDfK)]2 in blood, kidneys, liver, and lungs, and increase target-to-background (T/B) ratios at >30 min postinjection. E and K may have advantages over PEG4 due to a combination of relatively low liver uptake and high tumor/liver and tumor/lung ratios of ternary ligand complexes [99mTc(HYNIC-PKM-SU016)(tricine)(TPPTS)] (PKM = E and K).
29
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Roland Haubner, Hans‐Jürgen Wester, Ute Reuning et al. · PubMed · 1999 · 356 citations
Medicine, Oncology, Pharmacology +17
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Marcel L Janssen, Wim J.G. Oyen, Ingrid Dijkgraaf et al. · PubMed · 2002 · 331 citations
Medicine, Cell Biology, Oncology +14